Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Apr 7, 2023; 29(13): 2001-2014
Published online Apr 7, 2023. doi: 10.3748/wjg.v29.i13.2001
Table 1 Clinical and pathological features in the training and test sets
Characteristics
Training set (n = 162)
Test set (n = 70)
P value
nMTM-HCC (n = 118)
MTM-HCC (n = 44)
P value
nMTM-HCC (n = 51)
MTM-HCC (n = 19)
P value
Age, mean ± SD60.6 ± 10.952.4 ± 9.9< 0.00160.7 ± 10.454.7 ± 9.70.0340.647
Sex (men, %)102 (86.4)42 (95.5)0.17939 (76.5)18 (94.7)0.1610.125
HBsAg (positive, %)91 (77.1)33 (75.0)0.77738 (74.5)14 (73.7)0.9440.712
AFP > 400 µg/L, n (%)18 (15.3)31 (70.5)< 0.00112 (23.5)9 (47.4)0.0530.970
CEA (ug/L)2.6 (2.1)2.7 (1.9)0.7192.2 (2.0)2.2 (1.2)0.5430.332
CA19-9 (U/mL)15.0 (19.3)28.0 (25.4)0.02116.7 (17.1)16.0 (34.4)0.6870.770
PLT (× 109/L)135.0 (83.0)174.0 (88.5)0.027135.0 (57.0)175.0 (127.0)0.0010.970
TBIL (µmol/L)16.6 (10.8)20.7 (9.8)0.06715.7 (10.3)14.4 (7.6)0.9160.509
DBIL (µmol/L)3.8 (2.6)4.8 (2.9)0.0603.2 (2.1)3.3 (2.7)0.6200.419
IBIL (µmol/L)12.5 (7.0)15.0 (7.4)0.13612.2 (7.8)10.9 (4.5)0.7120.061
Albumin, mean ± SD37.8 ± 5.037.0 ± 5.80.38737.8 ± 5.038.3 ± 5.10.7150.647
AST (U/L)32.0 (23.5)43.0 (68.8)0.00433.0 (29.0)43.0 (61.0)0.1350.980
ALT (U/L)31.5 (34.0)46.0 (64.0)0.02328.0 (35.0)57.0 (96.0)0.0740.748
AST/ALT1.1 (0.6)1.1 (0.5)0.7021.3 (0.5)1.1 (0.7)0.2070.842
Edmondson-Steiner grade (III-IV, %)38 (32.2)18 (40.9)0.30014 (27.5)10 (52.6)0.0480.967
Microvascular invasion, n (%)56 (47.5)20 (45.5)0.82018 (35.3)10 (52.6)0.1880.331
Satellite nodules, n (%)9 (7.6)5 (11.4)0.4521 (2.0)1 (5.3)0.4610.110
Biliary invasion, n (%)4 (3.4)1 (2.3)0.7152 (3.9)1 (5.3)0.8050.646